Cognition Therapeutics shares rose 30% pre-market after the FDA confirmed its Phase 3 trial for Alzheimer's drug Zervimesine.

Women with Down syndrome have more advanced signs of Alzheimer’s disease than men do, according to research.However, the ...

This insight points to the need for more sex-specific approaches in both Alzheimer’s research and treatment planning, ...

UC Irvine researchers found that women with Down syndrome have more advanced Alzheimer’s pathology than men at the same age ...

Anavex Life Sciences Corp (AVXL) reports a robust financial runway and unveils encouraging results for blarcamesine, despite ...

A new study by researchers at the University of California, Irvine has revealed that women with Down syndrome exhibit more ...

Cognition Therapeutics Inc (NASDAQ:CGTX) saw its stock jump 27% following FDA confirmation that the company’s proposed Phase ...

Anavex faces dilution risk from its $150M ATM facility, high cash burn, and lack of revenue. Click here to see why AVXL stock ...

Q2 2025 Earnings Call Transcript August 12, 2025 Acumen Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.68 EPS, expectations were $-0.54. Operator: Good day, and welcome to ...

Marmosets used to study aging and menopause at a University of Massachusetts laboratory were euthanized two months before the ...

Researchers at Arizona State University have developed a breakthrough diagnostic tool that could transform how quickly and ...

Our expert-tested picks will help you keep on top of your heart health, whether you’ve been diagnosed with hypertension or ...